357617-14-2

Upstream product

• 61338-96-3 3,4-bis(benzyloxy)-2-fluorobenzaldehyde 
• 104324-18-7 (4S)-3-(isothiocyanoacetyl)-4-(phenylmethyl)-2-oxazolidinone 

Downstream Products

• 357617-18-6 (4S,5R)-5-[3,4-bis(benzyloxy)-2-fluorophenyl]-2-thioxooxazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 4-methyl ester 
• 357617-20-0 (4S,5R)-5-[3,4-bis(benzyloxy)-2-fluorophenyl]-2-oxooxazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 4-methyl ester 
• 357617-22-2 (2S,3R)-3-[3,4-bis(benzyloxy)-2-fluorophenyl]-2-tert-butoxycarbonylamino-3-hydroxypropionic acid methyl ester 
• 357617-26-6 (2S,3R)-2-amino-3-[3,4-bis(benzyloxy)-2-fluorophenyl]-3-hydroxypropionic acid 
• 357617-16-4 (4S,5R)-5-[3,4-bis(benzyloxy)-2-fluorophenyl]-2-thioxooxazolidine-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of 2-fluoro- and 6-fluoro-(2S,3R)-(3,4-dihydroxyphenyl)serine as potential in vivo precursors of fluorinated norepinephrines

The title compounds were prepared by the aldol condensation of 3,4-dibenzyloxy-2-fluorobenzaldehyde and 4,5-dibenzyloxy-2-fluorobenzaldehyde with the oxazolidinone 2, a chiral glycine equivalent. Removal of the chiral auxiliary and blocking groups produced the target amino acids 2-fluoro- and 6-fluoro-(2S,3R)-(3,4-dihydroxyphenyl)serine (1b and 1c) in >98% ee.